- Home
- GGZ vs IRWD Comparison
GGZ vs IRWD Comparison
Compare GGZ & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGZ
- IRWD
- Stock Information
- Founded
- GGZ 2013
- IRWD 1998
- Country
- GGZ United States
- IRWD United States
- Employees
- GGZ N/A
- IRWD N/A
- Industry
- GGZ Investment Managers
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- GGZ Finance
- IRWD Health Care
- Exchange
- GGZ Nasdaq
- IRWD Nasdaq
- Market Cap
- GGZ 105.1M
- IRWD 124.0M
- IPO Year
- GGZ N/A
- IRWD 2010
- Fundamental
- Price
- GGZ $13.44
- IRWD $0.72
- Analyst Decision
- GGZ
- IRWD Buy
- Analyst Count
- GGZ 0
- IRWD 5
- Target Price
- GGZ N/A
- IRWD $4.94
- AVG Volume (30 Days)
- GGZ 12.8K
- IRWD 1.7M
- Earning Date
- GGZ 01-01-0001
- IRWD 08-07-2025
- Dividend Yield
- GGZ 5.39%
- IRWD N/A
- EPS Growth
- GGZ N/A
- IRWD N/A
- EPS
- GGZ 1.75
- IRWD N/A
- Revenue
- GGZ N/A
- IRWD $317,676,000.00
- Revenue This Year
- GGZ N/A
- IRWD N/A
- Revenue Next Year
- GGZ N/A
- IRWD N/A
- P/E Ratio
- GGZ $6.79
- IRWD N/A
- Revenue Growth
- GGZ N/A
- IRWD N/A
- 52 Week Low
- GGZ $9.43
- IRWD $0.53
- 52 Week High
- GGZ $12.50
- IRWD $7.11
- Technical
- Relative Strength Index (RSI)
- GGZ 60.33
- IRWD 50.80
- Support Level
- GGZ $13.44
- IRWD $0.70
- Resistance Level
- GGZ $13.67
- IRWD $0.82
- Average True Range (ATR)
- GGZ 0.11
- IRWD 0.06
- MACD
- GGZ -0.01
- IRWD 0.00
- Stochastic Oscillator
- GGZ 67.65
- IRWD 34.46
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.